These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 37200021

  • 1. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
    JAMA Oncol; 2023 Jul 01; 9(7):919-927. PubMed ID: 37200021
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W, Thong E, Andrabi S, Verma V, Brian Butler E, Teh BS.
    J Clin Neurosci; 2021 Mar 01; 85():115-121. PubMed ID: 33581781
    [Abstract] [Full Text] [Related]

  • 4. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow CJ, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC.
    J Neurooncol; 2024 Jan 01; 166(1):73-78. PubMed ID: 38114801
    [Abstract] [Full Text] [Related]

  • 5. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
    Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.
    Acta Neuropathol Commun; 2016 Aug 08; 4(1):79. PubMed ID: 27503138
    [Abstract] [Full Text] [Related]

  • 6. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    Haque W, Teh C, Butler EB, Teh BS.
    J Neurooncol; 2022 Mar 17; 157(1):137-146. PubMed ID: 35103907
    [Abstract] [Full Text] [Related]

  • 9. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.
    Pathol Res Pract; 2018 Jun 17; 214(6):881-888. PubMed ID: 29650441
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A.
    J Clin Oncol; 2020 Oct 10; 38(29):3407-3417. PubMed ID: 32706640
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.
    Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, Wang Y.
    Cancer Biol Med; 2021 Feb 15; 18(1):272-282. PubMed ID: 33628600
    [Abstract] [Full Text] [Related]

  • 12. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 14. High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase.
    Liu Y, Li Y, Wang P, Chen L, Feng J, Qiu X.
    Radiat Oncol; 2021 Aug 19; 16(1):157. PubMed ID: 34412650
    [Abstract] [Full Text] [Related]

  • 15. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.
    J Neurooncol; 2015 Sep 19; 124(2):197-205. PubMed ID: 26033545
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas.
    Li M, Liu J, Weng J, Dong G, Chen X, Cui Y, Ren X, Shen S, Jiang H, Zhang X, Zhao X, Li M, Wang X, Ren H, Li Q, Zhang Y, Cheng Q, Yu Y, Lin S.
    Cancer Sci; 2024 Oct 19; 115(10):3403-3414. PubMed ID: 39101880
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W.
    Neuro Oncol; 2018 Feb 19; 20(3):367-379. PubMed ID: 29016808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.